Edwards Lifesciences Reports 9% Sales Increase

By Tamara Parker • Wednesday, February 12 06:08 • Permanent Link

Edwards Lifesciences (NYSE: EW) reported fourth-quarter sales of $1.39 billion, representing a 9% increase. Transcatheter aortic valve replacement (TAVR) sales grew by 6%, reaching $1.04 billion, with constant currency sales up by 5%. Additionally, transcatheter mitral and tricuspid therapies (TMTT) sales surged by 88% to $105 million. Full-year 2024 global sales for TAVR reached $4.1 billion, marking a 6% increase year-over-year. TMTT's full-year sales of $352 million reflected a substantial 78% increase compared to the previous year.

The company's gross profit margin for the quarter was 78.9%, or 79.0% adjusted, compared to 80.2% in the same period last year. Selling, general, and administrative expenses in the fourth quarter were $492 million, accounting for 35.5% of sales, an increase from $417 million in the prior year. Research and development expenses grew by 12% over the prior year, reaching $271 million, or 19.6% of sales.

Edwards Lifesciences is reiterating its 2025 constant currency sales growth of 8% * 10% and an adjusted EPS of $2.40 * $2.50. The company anticipates a mid-year asymptomatic TAVR indication approval in the U.S. and increasing contributions from an expanding set of structural heart therapies in 2026 and beyond.

The company's operating profit margin in the fourth quarter was 22.6%, or 25.6% adjusted, in line with expectations. Cash and cash equivalents were approximately $3.0 billion as of December 31, 2024, while total debt was approximately $600 million.

For the first quarter of 2025, Edwards Lifesciences projects total sales to be between $1.35 and $1.43 billion, with adjusted EPS expected to range from $0.58 to $0.64.

Edwards Lifesciences is a leading global structural heart innovation company, focusing on improving patient lives through breakthrough technologies and partnerships with clinicians and healthcare stakeholders. Following these announcements, the company's shares moved -0.3%, and are now trading at a price of $70.91. For the full picture, make sure to review Edwards Lifesciences's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.